The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali

Ayu Dewi Ni Nyoman¹, Ni Made Pramita Widya Suksmarini², Anak Agung Ngurah Satya Pranata², Andreliano Yosua Rompis², I Wayan Juli Sumadi³

¹Department of Biochemistry, Faculty of Medicine, Udayana University, Jl. PB Sudirman, Denpasar 80232, Indonesia
²Faculty of Medicine, Udayana University, Jl. PB Sudirman, Denpasar, 80232 Indonesia
³Department of Pathology, Faculty of Medicine, Udayana University, Jl. PB Sudirman, Denpasar 80232, Indonesia

*Corresponding author: ayu.dewi@unud.ac.id

ABSTRACT Mutations in the KRAS (Kirsten rat sarcoma viral oncogene homolog gene) and BRAF (v-Raf murine sarcoma viral oncogene homolog B1) gene play a significant role in primary resistance to colorectal cancer therapy. Around 85-90% of KRAS mutations in colorectal cancer occur in exon 2 (codon 12 and 13), whereas approximately 96% of BRAF mutations occur in exon 15 codon 600 (V600E). This study aimed to determine the prevalence and mutation characteristics of the KRAS and BRAF genes in colorectal cancer patients in Bali. The DNA was isolated from 44 formalin-fixed paraffin-embedded colorectal cancer samples which were stored in the Department of Pathology, Sanglah General Hospital in 2017. Detection of mutation was carried out by polymerase chain reaction (PCR) and direct sequencing. Out of 44 samples, only 27 were successfully amplified and sequenced. Our findings showed six samples (22.2%) with mutated KRAS at codons 12 and 13 (including two samples with G12D, one sample with G12V, and three samples with G13D). Interestingly, we found three samples (11.1%) of BRAF mutation, including two samples with V600E mutation and one with V600L mutation. Taken together, our results showed that KRAS and BRAF mutations were identified and occurred exclusively. Further studies are essential to identify the correlation of these mutations with colorectal cancer prognosis and response to chemotherapy.

KEYWORDS BRAF; colorectal cancer; gene mutation; KRAS

1. Introduction

Colorectal cancer (CRC) is a malignancy that occurs in the colon or rectum. Colorectal cancer ranks third in most types of cancer suffered in the world. The number of new cases of colorectal cancer in the world reached 1.8 million in 2018 (Globocan- The Global Cancer Observatory 2019), whereas in Indonesia, there have been 30,017 cases (World Health Organization 2019). The absence of population-based data in Indonesia leads to an unclear overview of the incidence of CRC. Various reports show increases in the number of cases of CRC as one of the ten most common cancers (Warsinggih et al. 2020). These indicate that colorectal cancer is one of the concerned health problems.

Current evidence showed both genetic and epigenetic contribution to the development of colorectal cancer pathogenesis. It consists of three main pathways, namely chromosomal instability (CIN), group microsatellite instability (MSI), and methylation on CpG island/CpG island methylator phenotype (CIMP). From all these three mechanisms, most colorectal cancer development is related to the CIN pathway. The CIN pathway involves alterations in the RAS/RAF/MEK/ERK signaling cascade that regulates cell proliferation, differentiation, motility, and apoptosis (Kuipers et al. 2015).

The mutated RAS gene is found in more than 30% of cancers that occur in humans. Mutations in the KRAS gene occur with the highest frequency (21.6%), followed by NRAS (8.0%) and HRAS (3.3%) (Arrington et al. 2012). In colorectal cancer, KRAS genes that undergo mutations contribute to 40% of cases. This protein can convey external signals to the nucleus by encoding a protein bound to guanosine triphosphate (GTP) that regulates cell division (Arrington et al. 2012). If a mutation occurs, the KRAS gene will be impaired to switch between active and inactive states. Mutations due to changes nucleotide bases in codons 12 and 13 will change the encoded amino acids, causing the KRAS gene to be constitutively active and undergo proliferation. Approximately 85-90% of KRAS mutations in exon 2 (codon 12 and 13) contribute to colorectal cancer. KRAS mutation G12D, G12V, and G13D were the most prevalent. Notably, not all mutations of KRAS predict poor prognosis in patients with CRC. Only G12D
and G12V mutations in codon 12 of KRAS were independent prognostic factors of worse overall survival and progression-free survival for CRC patients (Li et al. 2019). BRAF mutation mostly (96%) occurs in exon 15 of codon 600 or known as V600E mutation. Epidemiological studies showed that mutations in the BRAF gene occur in 5-15% of colorectal cancer. In addition, a case study conducted on 2,530 patients found that the prevalence of BRAF mutations was 9.1% (Seligmann et al. 2017). BRAF mutations can be a biomarker to determine the prognosis and therapy of colorectal cancer. In terms of prognosis, BRAF mutations are associated with poor prognosis and reduced overall survival in colorectal cancer patients (Wang et al. 2019). As for treatment, BRAF mutation plays a role in choosing the type of regimen therapy that affects the outcomes (Kopetz et al. 2015).

As concluded from various findings, the KRAS exon two mutation and BRAF V600E mutation is an important predictive and prognostic biomarker in colorectal cancer. However, data on the prevalence and mutation characteristics of exon two codon 12 and 13 KRAS gene also BRAF V600E in colorectal cancer patients in Bali are limited. Thus, we sought to identify the prevalence and characteristics of amino acid alterations of KRAS and BRAF mutations through this study.

2. Materials and Methods

2.1. Ethics
The study was reviewed and approved by the ethics committee of the Faculty of Medicine, Udayana University (number: 400/UN14.2.2.VII.14/LP/2020).

2.2. Samples
Samples used in this study were 44 formalin-fixed paraffin-embedded (FFPE) stored at the Department of Pathology, Sanglah General Hospital, which were histologically confirmed as colorectal cancer specimens in 2017.

2.3. DNA extraction from FFPE samples
DNA was extracted according to the Black Prep FFPE DNA Kit (Analytic Jena GmbH, Germany). Briefly, 2 × 10 μm FFPE slices were lysed with 400 μL Lysis Solution MA and 40 μL Protease K. After incubation at 65 °C for one hour, samples were then incubated at 90°C for one hour in a thermal mixer at 1,000 rpm. Following incubation for 5 min at room temperature, the sample was centrifuged at 13,000 rpm for 2 min. The supernatant was transferred into a 1.5 mL microcentrifuge tube and 400 μL absolute ethanol 99% was added. The sample was transferred into the spin column and centrifuged at 12,000 rpm for 1 min. The sequential washing steps were carried out using 500 μL Washing Solution C and 650 μL Washing Solution BS, each centrifuged at a speed of 12,000 rpm for 1 min. After washing with 650 μL of 99% absolute ethanol and centrifuged at a speed of 12,000 rpm for 1 min, DNA was eluted in 100 μL elution buffer and centrifuged at 12,000 rpm for 1 min. The concentration of isolated DNA was then measured using SimpliNano (Biochrom).

2.4. KRAS and BRAF PCR amplification
Exon 2 of the KRAS gene was amplified using the following primers (Macrogen, Korea): forward 5’GGTACTGCTGGAGTATTGTAGT3’ and reverse primer 5’CATGAAAATGTCAGAGAACC’3, whereas the BRAF gene was amplified using forward primer 5’TGCTTGGCTGTAGAAGAAATG3’ and reverse primer 5’TGCCTTCTCTGATAGAAATGA3’. Amplification was carried out in a total volume of 10 μL containing 5 μL master mix, 0.2-0.3 μL for each forward and reverse primer either KRAS gene or BRAF gene (10 μM), 0-1.6 μL ddH2O and 3-4.6 μL of 10 ng/μL DNA. PCR program or KRAS was carried out at 95 °C for 5 min and followed by 40 cycles of denaturation at 95 °C for 15 s, annealing at a temperature range of 50-56 °C for 60 s and extension at 72 °C for 30 s and a final elongation step at 72 °C for 5 min. For the BRAF PCR amplification, the program was carried out at 95 °C for 5 min, followed by 40 cycles of denaturation at 95 °C for 30 s, annealing at 50 °C for 30 s, extension at 72 °C for 40 s and a final extension step at 72 °C for 5 min. The length of the amplicon for KRAS was 288 bp, whereas BRAF was 165 bp. PCR product was applied into 2% gel agarose dissolved in 1X TBE buffer.

2.5. KRAS and BRAF direct sequencing
KRAS mutations in exon two and BRAF V600E mutation were identified by direct sequencing. PCR products were sent to the Genetika Science Laboratory, Jakarta. Direct sequencing was done using BigDye (Applied Biosystems).

3. Results and Discussion

3.1. Characteristics of patients
Twenty-five (57%) patients were male and 19 (43%) patients were female and most of them (34 out of 44, or 77%) were more than 50 years old. Based on colorectal cancer histological type, we identified 37 (84%) samples classified as adenocarcinoma, 6 (14%) samples were mucinous adenocarcinoma and 1 (2%) sample were intramuscosal adenocarcinoma (Table 1).

3.2. KRAS and BRAF mutation
Out of 44 samples, there were only 27 samples in which DNA could be successfully amplified. The overall KRAS mutation rate was 22.2% (6/27). From all 6 KRAS mutated samples, three samples showed mutations in codon 12, in-
alteration of valine (GTG) to glutamic acid (GAG) (Figure 2a and 2b). The BRAF V600L mutation was marked with alteration of valine (GTG) to leucine (TTG) (Figure 2c). The frequency and amino acid change of KRAS and BRAF mutation are shown in Table 2.

### 3.3. Discussion

Patient data in the form of age, gender, and histology characteristics were taken from the Department of Pathology, Sanglah Hospital’s medical record in 2017. Samples were found to be in the age range of 23 to 80 years old. The results showed that the incidence of colorectal cancer was more in the age group of more than 50 years old. This shows conformity with previous publications that most sufferers are over 50 years old ([Kuipers et al. 2015](#)).

Our results showed that the incidence of colorectal cancer was higher in men than in women. [Indrayani and Sриwidyani (2017)](#) showed that cases of colorectal cancer in males were found in 16 (70%) of 23 samples. These findings are consistent with data published by [Globocan-The Global Cancer Observatory (2019)](#) that stated the standardized incidence rate of colorectal cancer age in the world for male are higher than female (23.6 compared to 16.3 per 100,000 people). The results of the study are also consistent with data from the [World Health Organization (2019)](#) that the incidence rate of standardized colorectal cancer in Indonesia for males is higher than females of 7.7 and 4.4 per 100,000 people. The data show that the incidence of colorectal cancer is consistently higher in males than in the female.

In our study, the most prominent type of colorectal cancer was adenocarcinoma, followed by mucinous adenocarcinoma and intramucosal adenocarcinoma. This result shows concordance with studies that about 95% of the histology of colorectal cancer is adenocarcinoma, and the rest are other types, namely mucinous carcinoma and adenosquamous carcinoma ([American Institute of Cancer Research 2018](#)).

| Characteristics          | N (%) |
|--------------------------|-------|
| Age (years)              |       |
| <50                      | 10 (23)|
| >50                      | 34 (77)|
| Gender                   |       |
| Male                     | 25 (57)|
| Female                   | 19 (43)|
| Histology                |       |
| Adenocarcinoma, NOS      | 37 (84)|
| Mucinous adenocarcinoma  | 6 (14)|
| Intramucosal adenocarcinoma | 1 (2) |

NOS, not otherwise specified

### 3.3.1. Table 2 Frequency of KRAS and BRAF mutations

| Nucleotide change | Amino acid change | No. of mutated cases |
|-------------------|-------------------|----------------------|
| KRAS (n=27)       |                   |                      |
| c.35G>A           | p.G12D            | 2                    |
| c.35G>T           | p.G12V            | 1                    |
| c.38G>A           | p.G13D            | 3                    |
| KRAS codon 13     |                   |                      |
| KRAS (n=27)       |                   |                      |
| c.1799T>A         | p.V600E           | 2                    |
| c.1798G>T         | p.V600L           | 1                    |
| BRAF (n=27)       |                   |                      |
| BRAF codon 600    |                   |                      |

- Figure 1: KRAS mutations at exon 2 codon 12 and 13 from 3 different samples. The electropherograms display mutations of KRAS G12D (G→A) (a), KRAS G12V (G→T) (b), and KRAS G13D (G→A) (c).
Out of 44 samples, there were 17 samples in which DNA could not be successfully amplified. The reason might be because the DNA was degraded due to the use of FFPE. Evaluation of the degree of DNA degradation is of major importance when handling FFPE samples. Solassol et al. (2011) compared the degradation level of DNA isolated from frozen samples and FFPE using a 2% agarose gel electrophoresis. They found that the frozen samples were not degraded, whereas the FFPE samples were partially fragmented. However, they observed a correct PCR amplification in both the FFPE and frozen tissues, demonstrating that the PCR conditions were adapted to the FFPE samples. In our study, we re-isolated and re-PCR amplified for the samples with suspected DNA degradation, but we still obtained PCR amplification unsuccessfully and/or the sequencing data. Thus, the samples could not be analyzed. Therefore, we excluded those samples for analysis.

The results of other studies showed a different prevalence of KRAS mutation which is 31% (Phipps et al. 2013), 40% (Imamura et al. 2014), and 33.3% (Phua et al. 2015). In contrast, studies in Indonesia with a small size of samples showed a prevalence of KRAS mutation was 30% (Mastutik et al. 2016) and 60.9% (Indrayani and Sriwidyan 2017). The RASCAL study (Arrington et al. 2012) reported mutations in codon 12 in 27.7% of cases. Jones et al. (2017) stated that mutations in codon 12 were found at the most, as many as 34.6% of cases. However, it is different from research published by Indrayani and Sriwidyan (2017) that the mutation of exon two codon 12 KRAS gene was found in 9 (39%) of 23 samples. Our findings showed that 2 (7.4%) out of 27 samples had G12D mutations, and 1 (3.7%) of 27 samples had G12V mutations. The results agreed with the RASCAL study that codon 12 with the highest prevalence were G12D mutations, followed by G12V, G12C, G12S, G12A, and G12R (Arrington et al. 2012). Jones et al. (2017) also described that the G12D mutation was more than G12V mutations (36% and 30.1%, respectively).

G13D variation is the most common variation in exon two codon 13 KRAS gene mutation. A report from Singapore General Hospital from June 2010 to October 2012 showed the prevalence of mutations in codons 13 as many as 8.9% (4 out of 45 samples) and 100% (4 out of 4 samples) had variations in the G13D mutation (Phua et al. 2015). Indrayani and Sriwidyan (2017) analyzed KRAS mutation from 23 CRC FFPE samples in Sanglah Hospital using HRM PCR. They found 14 (60.9%) cases had KRAS mutation with 9 cases with codon 12 mutation, 4 cases with codon 13 mutation, 1 case with codon 59 mutation and 1 case with codon 117 mutation. However, they did not provide specific data on the characteristics and type of those mutations.

The frequency of the BRAF V600E mutation found in this study is different from the study conducted in the Middle East with the number of BRAF gene mutation were 19 (2.5%) out of 757 samples and 17 (90%) samples were BRAF V600E mutations (Siraj et al. 2014). Shimada et al. (2018) showed that the BRAF V600E mutation was found in 7 out of 98 samples. In addition, a study conducted by Taniguchi et al. (2020) showed the percentage of BRAF V600E mutations was 34 (10.5%) out of 324 samples. Difference results were also found in the study conducted in Mexico, Latin America and the Caribbean population, which was 4% and 7.8%, respectively (Hernández-Sandoval et al. 2020). Meanwhile, different results were also found in Indonesia, showing BRAF V600E mutation in 6 (14%) of 43 samples (Warsinggih et al. 2020) and another study identified no BRAF mutation (Ni Nyoman et al. 2020). Another mutation of BRAF non-V600E was found in this study, with a change in a valine (GTG) to leucine (TTG) or known as V600L. A study conducted by Mao et al. (2012) in the Chinese patients showed different results with the frequency of V600L mutations in 6 (10.2%) out of 59 cases of colorectal cancer. This study also found
other types of non-V600E mutations, namely V600Q in 2 (3.4%) cases and V600V in 1 (1.7%) case. BRAF mutation is much higher in this study than in other studies and frequently overlaps with KRAS mutations.

The difference percentage of mutation found in this study may be affected by the small number of samples. The larger number of samples used will result in the possibility of more mutation cases. In addition, the difference in the frequency of mutations found can also be attributed to race or ethnicity. KRAS mutation rates were highest in tumors from blacks (44.1%), followed by tumors from Asians (27.8%) and whites (34.9%). BRAF V600E mutation was higher in white people (13.9%) than in black people (6.4%) and Asians (5.6%). Wild-type KRAS and BRAF tumors were most common among Asians (66.7%), and the frequency differed compared with tumors from blacks (49.5%) or whites (51.2%) (Yoon et al. 2015).

Up to now, KRAS mutations have been identified as a predictive marker of resistance to anti-EGFR in patients with metastatic CRC, and the use of anti-EGFR is restricted to the patients with wild-type KRAS (Mao et al. 2012). Although the KRAS status helps identify patients who are unlikely to benefit from anti-EGFR therapy, not all patients with wild-type KRAS respond to anti-EGFR therapy (Zhao et al. 2017). It remains unclear why a large number of patients with wild-type KRAS tumors are still not responsive to the treatment. Major downstream pathways activated by EGFR, including the RAS-RAF-MAPK and PI3K-PTEN-AKT signaling pathways, are important for generating resistance to anti-EGFR. BRAF, a downstream effector of RAS in the EGFR pathway, has been a subject of focus. Mutations of KRAS and BRAF genes are frequently mutually exclusive in colorectal cancer (Mao et al. 2012).

Early detection of mutations in colorectal cancer patients is very important to improve the outcome. Changes in coded amino acids resulting from changes in the nucleotides that make up the codon cause either the KRAS or BRAF gene to be in a constitutively active state. Circumstances such as those that trigger excessive proliferation and inhibition of apoptosis, thus leading to the emergence of cancer and resistance to anti-EGFR therapy and RAF inhibitor therapy, such as panitumumab and cetuximab in the treatment of colorectal cancer (Phua et al. 2015; Zhao et al. 2017). In addition to determining the appropriate therapy, the KRAS mutation has also been a predictive factor for prognosis in colorectal cancer patients. A 5-year progression-free survival in patients with KRAS gene mutations was lower (74.5%) than patients with normal KRAS genes (85.9%) (Li et al. 2019). BRAF mutation also contributed to determining the regimen in cancer patients. RAF inhibitors such as vemurafenib only produce 5% of response therapy in patients with BRAF mutation than wild-type patients (Kopetz et al. 2015). Therefore, identification of KRAS and/or BRAF mutation in a clinical setting is beneficial for treatment cost-effectiveness and is important to plan the proper chemotherapy for the patients. In this study, we did not analyze the correlation between KRAS or BRAF mutation and response therapy due to insufficient data in the medical record. Because this research was a retrospective study with a limited sample size and was conducted only in a single hospital, it may have introduced some selection bias. All are considered the limitation of the study.

4. Conclusions

In conclusion, our result showed that colorectal cancer cases in Bali were more common in males and increased with age. KRAS mutations have been identified in exon 2, and the most frequent is G13D, followed by G12D and G12V. Interestingly, in addition to BRAF V600E mutations in exon 15, we also identified BRAF V600L mutation. Although the sample size in this study is small and cannot yet be generalized to the Indonesian population, our finding contributes to the data on the prevalence and characteristics of KRAS and BRAF mutation in colorectal cancer patients in Bali, whose data is very restricted. Importantly, BRAF V600L mutation, as far as we know, has not been published in colorectal cancer patients in Indonesia. Further studies with a sufficient number of samples are needed to obtain conclusive data on the relationship between these gene mutations and the response to therapy and prognosis of colorectal cancer.

Acknowledgments

This study was supported by the Udayana University research grant (grant number B/20-69/UN14.4.A/PT.01.05/2020). The authors would like to thank Senshi Septiasari, Nanik Astuti, and Nyoman Sri Handayani for their technical help.

Authors’ contributions

NNAD designed this study and conducted manuscript proofreading before submission. NMPWS, AANSP and AYR carried out laboratory work and analyzed the data. NNAD and IWJS advised the laboratory techniques. All authors read and approved the final version of the manuscript.

Competing interests

The authors declare no competing interests.

References

American Institute of Cancer Research. 2018. Diet, nutrition, physical activity and colorectal cancer. Contin. Updat. Proj. p. 42-44. URL http://www.aicr.org/continuous-update-project/reports/breast-cancer-report-2017.pdf.
Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-Aguilar J, Kim J. 2012. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int. J. Mol. Sci. 13(10):12153–12168. doi:10.3390/ijms131012153.

Globocan- The Global Cancer Observatory. 2019. Colorectal cancer Source: Globocan 2018. Globocan 2018 876:1–2.

Hernández-Sandoval JA, Gutiérrez-Angulo M, Magaña-Torres MT, Alzivo-Rodríguez CR, Ramírez-Plascencia HHH, Flores-López BA, Valenzuela-Pérez JA, Peregrina-Sandoval J, Moreno-Ortiz JM, Domínguez-Valentín M, Ayala-Madrígal MDLL. 2020. Prevalence of the BRAF p.v600e variant in patients with colorectal cancer from Mexico and its estimated frequency in Latin American and Caribbean populations. J. Investig. Med. 68(5):985–991. doi:10.1136/jim-2020-001301.

Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian J, Chen Q. 2012. KRAS, BRAF and PIK3CA mutations in colorectal cancer. Nat. Rev. Dis. Prim. 1(February 2016):1–25. doi:10.1038/nrdp.2015.65.

Li W, Liu Y, Cai S, Yang C, Lin Z, Zhou L, Liu L, Cheng X, Zeng W. 2019. Not all mutations of KRAS predict poor prognosis in patients with colorectal cancer. Int. J. Clin. Exp. Pathol. 12(3):957–967.

Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen H, Tang J, Chen Q. 2012. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One 7(5):1–7. doi:10.1371/journal.pone.0036653.

Masutwik G, Rahniayu A, Rahaju A, Kurniasari N, I’tishom R. 2016. Status mutasi gen kras kodon 12 dan 13 di adenocarcinoma kolorektal [The mutation status of kras gene codon 12 and 13 in colorectal adenocarcinoma]. J. Clin. Pathol. Med. Lab. 23(1):12–17. doi:10.24293/jcplm.v23i1.1177.

Ni Nyoman A, I Wayan J, Sun H. 2020. Molecular Profile of Colorectal Cancer Patients in Bali Based on Methylation of O6-Methylguanine DNA Methyltransferase Promoter Region and Mutation of BRAF and Kirsten RAt Sarcoma Viral Oncogene Homolog Gene. J. Med. Sci. 40(6):257–264. doi:10.4103/jmedsci.jmedsci_205_19.

Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, Potter JD, Newcomb PA. 2013. KRAS-mutation status in relation to colorectal cancer survival: The joint impact of correlated tumour markers. Br. J. Cancer 108(8):1757–1764. doi:10.1038/bjc.2013.118.

Phua LC, Ng HW, Yeo AH, Chen E, Lo MSM, Cheah PY, Chan EYC, Koh PK, Ho HK. 2015. Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer. Oncol. Lett. 10(4):2519–2526. doi:10.3390/ol.2015.3560.

Seligmann JF, Fisher D, Smith CG, Richman SD, Elliott Brown F, Adams R, Maughan T, Quirke P, Cheadle J, Seymour M, Middleton G. 2017. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Ann. Oncol. 28(3):562–568. doi:10.1093/annonc/mdw645.

Shimada Y, Tajima Y, Nagahashi M, Ichikawa H, Oyanagi H, Okuda S, Takabe K, Wakai T. 2018. Clinical significance of BRAF v600E mutations in colorectal cancer: a retrospective study of two institutions. J. Surg. Res. 232:72–81. doi:10.1016/j.jss.2018.06.020.

Siraj AK, Bu R, Prabhakaran S, Bavi P, Beg S, Al Hazmi M, Al-Rasheed M, Alobaisi K, Al-Dayel F, AlManea H, Al-Sanea N, Uddin S, Al-Kuraya KS. 2014. A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. Mol. Cancer 13(1):1–9. doi:10.1186/1476-4598-13-135.

Vo Thanh T, Bui M, Tran Q, Tran N, Do H, Pham A, Tran M. 2022. Tumour Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan. Transl. Oncol. 13(7):100786.
Wang J, Shen J, Huang C, Cao M, Shen L. 2019. Clinico-pathological significance of BRAFV600E mutation in colorectal cancer: An updated meta-analysis. J. Cancer 10(10):2332–2341. doi:10.7150/jca.30789.

Warsinggih, Liliyanto, Marhamah, Kusuma MI, Uwuratuw JA, Syarifuddin E, Faruk M. 2020. Relationship between BRAF V600E and KRAS mutations in stool for identifying colorectal cancer: A cross-sectional study. Ann. Med. Surg. 60(August):121–125. doi:10.1016/j.amsu.2020.10.027.

World Health Organization. 2019. Indonesia Source GLOBOCAN 2018. Int. Agency Res. Cancer 256:1–2.

Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA. 2015. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. J. Natl. Cancer Inst. 107(10):1–10. doi:10.1093/jnci/djv186.

Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, Yu Q, Yuan X. 2017. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget 8(3):3980–4000. doi:10.18632/oncotarget.14012.